Melinta Therapeutics
Melinta Therapeutics, founded in 2000 as Rib-X Pharmaceuticals, is an American publicly traded biopharmaceutical firm that focuses on the design and development of novel broad-spectrum antibiotics for the treatment of antibiotic-resistant infections in hospital and community settings. The company is located in New Haven, Connecticut.
In mid-2011, Sanofi entered into a global research collaboration and licensing option with the company to develop and commercialize novel antibiotics. It was renamed Melinta Therapeutics in 2013.
One of its products, delafloxacin, a fluoroquinolone antibiotic acquired from Wakunaga Pharmaceutical in 2006, was approved by the FDA in 2017.
As of 2016, the company was also developing radezolid, a next-generation oxazolidinone for bacterial acne.
Melinta moved its' headquarters to Morristown, New Jersey in early 2019.
On December 27, 2019, Melinta Therapeutics filed for Chapter 11 bankruptcy protection.
